How do I install the Icsm Consider Tt Normal Psa No Pca skill?

Run npx skillmds@latest add dromlakhani/icsm-consider-tt-normal-psa-no-pca in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Icsm Consider Tt Normal Psa No Pca safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Icsm Consider Tt Normal Psa No Pca?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Icsm Consider Tt Normal Psa No Pca free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Icsm Consider Tt Normal Psa No Pca?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Icsm Consider Tt Normal Psa No Pca by dromlakhani

Name: Icsm Consider Tt Normal Psa No Pca
Rating: 4.2 (5 reviews)
Author: dromlakhani

Icsm Consider Tt Normal Psa No Pca

Large RCTs show no increased prostate cancer risk with testosterone therapy in men without known prostate cancer and normal PSA, supporting its consideration in this population. This skill is triggered when a clinician evaluates a hypogonadal man with normal PSA and no prior cancer diagnosis and questions whether testosterone therapy is safe to initiate.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Consider testosterone therapy in men without known prostate cancer and normal PSA

STEP 1 — Gather Information

Collect symptoms of hypogonadism, confirm low total testosterone (<12 nmol/L or <350 ng/dL) on two morning fasting samples, obtain PSA (age‑appropriate normal, e.g., <4 ng/mL), perform DRE to exclude nodules or induration, and verify no history of prostate cancer.

STEP 2 — Rule In / Rule Out

If PSA is within normal limits, DRE is benign, and there is no personal history of prostate cancer, proceed to consider testosterone therapy; otherwise, defer testosterone therapy and refer for urology evaluation before initiation.

STEP 3 — Classify or Stratify

Classify the patient as having low prostate cancer risk based on normal PSA, benign DRE, and absence of known cancer, making testosterone therapy reasonable from an oncologic safety standpoint.

STEP 4 — Decide

Initiate testosterone therapy after shared decision‑making, targeting a mid‑normal testosterone range (approximately 350–750 ng/dL), and schedule baseline and follow‑up monitoring per guideline (symptoms, adverse events, testosterone, hematocrit, PSA, DRE at 3, 6, 6–12 months).

Clinical Guardrails / Mimics / Pitfalls

Do not start testosterone therapy if PSA is elevated or DRE is suspicious without urologic clearance; avoid in men with hematocrit >54% or untreated severe lower urinary tract symptoms; do not ignore the need for baseline and ongoing prostate cancer screening per evidence‑based guidelines; do not use testosterone therapy as monotherapy for erectile dysfunction without confirmed hypogonadism.

Concrete Clinical Example

A 55‑year‑old man presents with fatigue and low libido; two morning total testosterone measurements are 9 nmol/L, PSA is 1.2 ng/mL, DRE is smooth and non‑nodular, and he has no history of prostate cancer. After confirming hypogonadism and normal prostate assessment, the clinician discusses risks/benefits, initiates a transdermal testosterone gel, and arranges follow‑up at 3, 6, and 12 months for symptom response, hematocrit, PSA, and DRE.

Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036

---name: icsm-consider-tt-normal-psa-no-pcadescription: Large RCTs show no increased prostate cancer risk with testosterone therapy in men without known prostate cancer and normal PSA, supporting its consideration in this population. This skill is triggered when a clinician evaluates a hypogonadal man with normal PSA and no prior cancer diagnosis and questions whether testosterone therapy is safe to initiate.---# Consider testosterone therapy in men without known prostate cancer and normal PSA## STEP 1 — Gather InformationCollect symptoms of hypogonadism, confirm low total testosterone (<12 nmol/L or <350 ng/dL) on two morning fasting samples, obtain PSA (age‑appropriate normal, e.g., <4 ng/mL), perform DRE to exclude nodules or induration, and verify no history of prostate cancer.## STEP 2 — Rule In / Rule OutIf PSA is within normal limits, DRE is benign, and there is no personal history of prostate cancer, proceed to consider testosterone therapy; otherwise, defer testosterone therapy and refer for urology evaluation before initiation.## STEP 3 — Classify or StratifyClassify the patient as having low prostate cancer risk based on normal PSA, benign DRE, and absence of known cancer, making testosterone therapy reasonable from an oncologic safety standpoint.## STEP 4 — DecideInitiate testosterone therapy after shared decision‑making, targeting a mid‑normal testosterone range (approximately 350–750 ng/dL), and schedule baseline and follow‑up monitoring per guideline (symptoms, adverse events, testosterone, hematocrit, PSA, DRE at 3, 6, 6–12 months).## Clinical Guardrails / Mimics / PitfallsDo not start testosterone therapy if PSA is elevated or DRE is suspicious without urologic clearance; avoid in men with hematocrit >54% or untreated severe lower urinary tract symptoms; do not ignore the need for baseline and ongoing prostate cancer screening per evidence‑based guidelines; do not use testosterone therapy as monotherapy for erectile dysfunction without confirmed hypogonadism.## Concrete Clinical ExampleA 55‑year‑old man presents with fatigue and low libido; two morning total testosterone measurements are 9 nmol/L, PSA is 1.2 ng/mL, DRE is smooth and non‑nodular, and he has no history of prostate cancer. After confirming hypogonadism and normal prostate assessment, the clinician discusses risks/benefits, initiates a transdermal testosterone gel, and arranges follow‑up at 3, 6, and 12 months for symptom response, hematocrit, PSA, and DRE.**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036

Frequently asked questions